Advanced Colorectal Cancer
Conditions
Brief summary
The goal of this prospective observational study is to learn about the treatment decisions in advanced colorectal cancer treated with oxaliplatin and irinotecan. The main questions:1. learn about the efficacy and safety of immunotherapy or targeted drugs or other chemotherapy for patients treated with oxaliplatin and irinotecan（non-retreatment/rechallenge group，NR group）. 2. learn about the efficacy and safety of oxaliplatin or irinotecan for patients treated with oxaliplatin and irinotecan (retreatment/rechallenge group, RT/RC group). 3. compare the efficacy and safety of various treatment regimens for patients treated with oxaliplatin and irinotecan. This study will only collect the clinical data of patients, without any intervention, in the treatment services. All participants will be provided written informed consent as per the Declaration of Helsinki principles.
Interventions
None listed
Sponsors
Sun Yat-sen University
Study design
Observational model
COHORT
Time perspective
PROSPECTIVE
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
1. Phologically confirmed colorectal adenocarcinoma 2. Treated by oxaliplatin and irinotecan and discontinued due to progression or intolerable drug toxicity 3. ECOG 0-2 4. Predicted survival more than 3 months 5. Estimated by investigators that the main organ function is enough good to tolerate the next treatment plan. 6. Sign informed consent. 7. Agree to receive survival follow-up
Exclusion criteria
1. Previously exposed to regorafenib, furoquintinib, TAS-102, PD-1 inhibitors, or targeted drugs or immunotherapy for HER2 amplification, BRAF V600E mutation, and NTRK gene fusion. 2. Previously rechallenged or retreated by oxaliplatin or irinotecan after progression from chemotherapy regimens including oxaliplatin and irinotecan. 3. Participate in another interventional clinical study at the same time, unless in the follow-up stage of intervention study. 4. Proposed to use a treatment regimen containing regorafenib, furquintinib, and trifluridine, but has any problems obstacling oral drugs, such as inability to swallow, chronic diarrhea and intestinal obstruction et al. 5. Disagree to take contraceptive measures during the study treatment period or within 6 months after the end of the study treatment period. 6. Has other primary malignant tumor history, unless non-melanoma skin cancer or lentigo maligna or carcinoma in situ with sufficient treatment and no disease recurrence. 7. Has the history of allogeneic organ transplantation and allogeneic hematopoietic stem cell transplantation. 8. Has concomitant diseases that seriously endanger patient safety or affect patient completion of the study. 9. Has other problems that is not suitable for clinical research.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Progression free survival, PFS | Up to 12 months | PFS was calculated as the time from the date of treatment initiation to the date of disease progression or the last follow-up |
| Overall Survival, OS | Up to 24 months | OS was calculated as the time from the date of treatment initiation to the date of any cause of death, or the last follow-up. |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Objective response rate ，ORR | Up to 12 months | The ORR was defined as the percentage of patients performing a complete response (CR) or a partial response (PR) according to RECIST V1.1. |
| Adverse events, AEs | Up to 24 months | evaluated by NCI-CTC AE V5.0 |
| Disease Control Rate，DCR | Up to 12 months | The ORR was defined as the percentage of patients performing a complete response (CR) or a partial response (PR) or a stable disease (SD) according to RECIST V1.1. |
| Quality of life score | Up to 24 months | evaluated according to EORTC QLQ-C30 V3.0 |
| Comprehensive score of economic burden | Up to 24 months | evaluated according to COST-PROM |
Countries
China
Contacts
Primary ContactDongsheng Zhang, MD., phD.
Outcome results
None listed